246 related articles for article (PubMed ID: 31140861)
21. Ag+ Complexes as Potential Therapeutic Agents in Medicine and Pharmacy.
Hecel A; Kolkowska P; Krzywoszynska K; Szebesczyk A; Rowinska-Zyrek M; Kozlowski H
Curr Med Chem; 2019; 26(4):624-647. PubMed ID: 28933286
[TBL] [Abstract][Full Text] [Related]
22. Anticancer Activity and Modes of Action of (arene) ruthenium(II) Complexes Coordinated to C-, N-, and O-ligands.
Biersack B
Mini Rev Med Chem; 2016; 16(10):804-14. PubMed ID: 27161009
[TBL] [Abstract][Full Text] [Related]
23. Aminophosphonate metal complexes of biomedical potential.
Tušek-Božić LJ
Curr Med Chem; 2013; 20(16):2096-117. PubMed ID: 23432587
[TBL] [Abstract][Full Text] [Related]
24. Anticancer metallodrugs: where is the next cisplatin?
Hanif M; Hartinger CG
Future Med Chem; 2018 Mar; 10(6):615-617. PubMed ID: 29411994
[TBL] [Abstract][Full Text] [Related]
25. Study on the Synthesis of Methylated Reference and Their Application in the Quantity of Curcuminoids Using Single Reference Liquid Chromatography Based on Relative Molar Sensitivity.
Takahashi M; Morimoto K; Nishizaki Y; Masumoto N; Sugimoto N; Sato K; Inoue K
Chem Pharm Bull (Tokyo); 2022; 70(1):25-31. PubMed ID: 34980729
[TBL] [Abstract][Full Text] [Related]
26. Recent development of gold(I) and gold(III) complexes as therapeutic agents for cancer diseases.
Lu Y; Ma X; Chang X; Liang Z; Lv L; Shan M; Lu Q; Wen Z; Gust R; Liu W
Chem Soc Rev; 2022 Jul; 51(13):5518-5556. PubMed ID: 35699475
[TBL] [Abstract][Full Text] [Related]
27. Alkaloid-metal based anticancer agents.
Chen ZF; Liu YC; Huang KB; Liang H
Curr Top Med Chem; 2013; 13(17):2104-15. PubMed ID: 23978139
[TBL] [Abstract][Full Text] [Related]
28. Organometallic anticancer compounds.
Gasser G; Ott I; Metzler-Nolte N
J Med Chem; 2011 Jan; 54(1):3-25. PubMed ID: 21077686
[No Abstract] [Full Text] [Related]
29. Bioactive luminescent transition-metal complexes for biomedical applications.
Ma DL; He HZ; Leung KH; Chan DS; Leung CH
Angew Chem Int Ed Engl; 2013 Jul; 52(30):7666-82. PubMed ID: 23765907
[TBL] [Abstract][Full Text] [Related]
30. Discrimination of turmeric from different origins in China by MRM-based curcuminoid profiling and multivariate analysis.
Jia S; Sun Y; Li L; Wang R; Xiang Y; Li S; Zhang Y; Jiang H; Du Z
Food Chem; 2021 Feb; 338():127794. PubMed ID: 32798827
[TBL] [Abstract][Full Text] [Related]
31. Non-Curcuminoids from Turmeric and Their Potential in Cancer Therapy and Anticancer Drug Delivery Formulations.
Nair A; Amalraj A; Jacob J; Kunnumakkara AB; Gopi S
Biomolecules; 2019 Jan; 9(1):. PubMed ID: 30609771
[TBL] [Abstract][Full Text] [Related]
32. New applications of old metal-binding drugs in the treatment of human cancer.
Schmitt SM; Frezza M; Dou QP
Front Biosci (Schol Ed); 2012 Jan; 4(1):375-91. PubMed ID: 22202066
[TBL] [Abstract][Full Text] [Related]
33. Differential expression of CURS gene during various growth stages, climatic condition and soil nutrients in turmeric (Curcuma longa): Towards site specific cultivation for high curcumin yield.
Sandeep IS; Das S; Nasim N; Mishra A; Acharya L; Joshi RK; Nayak S; Mohanty S
Plant Physiol Biochem; 2017 Sep; 118():348-355. PubMed ID: 28697469
[TBL] [Abstract][Full Text] [Related]
34. Cyclometalated Ir(III) complexes as targeted theranostic anticancer therapeutics: combining HDAC inhibition with photodynamic therapy.
Ye RR; Tan CP; He L; Chen MH; Ji LN; Mao ZW
Chem Commun (Camb); 2014 Sep; 50(75):10945-8. PubMed ID: 25096019
[TBL] [Abstract][Full Text] [Related]
35. Phosphoroorganic Metal Complexes in Therapeutics.
Demkowicz S; Kozak W; Daśko M; Rachon J
Mini Rev Med Chem; 2016; 16(17):1359-1373. PubMed ID: 27145849
[TBL] [Abstract][Full Text] [Related]
36. Anticancer metallotherapeutics in preclinical development.
Kaluderović GN; Paschke R
Curr Med Chem; 2011; 18(31):4738-52. PubMed ID: 21919843
[TBL] [Abstract][Full Text] [Related]
37. Antioxidant activity of different species and varieties of turmeric (Curcuma spp): Isolation of active compounds.
Akter J; Hossain MA; Takara K; Islam MZ; Hou DX
Comp Biochem Physiol C Toxicol Pharmacol; 2019 Jan; 215():9-17. PubMed ID: 30266519
[TBL] [Abstract][Full Text] [Related]
38. Enzyme inhibition as a key target for the development of novel metal-based anti-cancer therapeutics.
Griffith D; Parker JP; Marmion CJ
Anticancer Agents Med Chem; 2010 Jun; 10(5):354-70. PubMed ID: 20380633
[TBL] [Abstract][Full Text] [Related]
39. "Good Fashion is Evolution, Not Revolution" - Methods to Enhance Existing Anticancer Medicines, Primarily with the Use of Transition Metal.
Guzowska M; Kalinowska M; Lewandowski W
Anticancer Agents Med Chem; 2018; 18(4):476-487. PubMed ID: 29189181
[TBL] [Abstract][Full Text] [Related]
40. Multi-Target Metal-Based Anticancer Agents.
Chen ZF; Orvig C; Liang H
Curr Top Med Chem; 2017 Nov; 17(28):3131-3145. PubMed ID: 28982336
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
